top of page

Pipeline
Pipeline
SCROLL DOWN
Pipeline
PROTIER Biotech develops a broad range of therapies based on innovative biotechnology.


PTB600
TARGET
GSPT1
INDICATION
Solid tumor
Hematologic malignancy
MODALITY
MG
DRUG CANDIDATE
Discovery
Candidate
Pre-clinical

Program
PTB700
TARGET
GSPT1
INDICATION
Multiple Myeloma
MODALITY
ADC Payload
(MG)
DRUG CANDIDATE
Discovery
Candidate
Pre-clinical

Program
PTB500
TARGET
Undisclosed
(First-in-class)
INDICATION
Ovarian cancer
MODALITY
MG
DRUG
Discovery
Candidate
Pre-clinical

Program
Discovery Target
TARGET
Undisclosed
(First-in-class)
Undisclosed
(First-in-class)
Undisclosed
INDICATION
Undisclosed
Undisclosed
Undisclosed
MODALITY
MG
MG
MG
DRUG
Discovery
Candidate
Pre-clinical
Program
PTB600
TARGET
GSPT1
INDICATION
Solid tumor Hematologic malignancy
MODALITY
MG
DRUG CANDIDATE
Candidate
PROGRAM

PTB700
TARGET
GSPT1
INDICATION
Multiple Myeloma
MODALITY
ADC Payload (MG)
DRUG CANDIDATE
Discovery
PROGRAM

PTB500
TARGET
Undisclosed(First-in-class)
INDICATION
Ovarian Cancer
MODALITY
MG
DRUG CANDIDATE
Candidate
PROGRAM

Discovery Target
TARGET
Undisclosed(First-in-class)
INDICATION
Undisclosed (3)
MODALITY
MG
DRUG CANDIDATE
Discovery
bottom of page
